Clinical Trial Monitoring Not Ready To Go Completely Off-Site, FDA Says
Agency yields to some, denies other industry requests in final guidance that declines to lay out one prescriptive monitoring path.
Agency yields to some, denies other industry requests in final guidance that declines to lay out one prescriptive monitoring path.